Capecitabine-induced hand foot syndrome: a brief look at possible pathways that may be associated with inflammation
ODÜ Tıp Dergisi · 2024
DOI: 10.56941/odutip.1453500 ↗Kurz gefasst
Fachartikel in der Zeitschrift ODÜ Tıp Dergisi, 2024. Verfasst von Evren Şavlı. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: The author declared that this study has received no financial support.
Abstract (Originalsprache)
Hand foot syndrome is a toxic reaction related to certain chemotherapy agents. Capecitabine is a prodrug used in the treatment of many cancers, such as gastrointestinal, biliary tract and breast cancers. It is associated with hand and foot syndrome (HFS), which preferentially affects palms and soles. There is still no consensus on effective international standard therapeutic strategies for the treatment and prevention of HFS because the underlying physiological and pharmacological mechanisms leading to the development of HFS have not been adequately explained. HFS is rarely life-threatening, but it may deteriorate the patient’s quality of life. Quitting or a reduction in the dose of the causative drug mostly provide the amelioration of the symptoms. The aim of this review is to briefly evaluate the possible inflammatory mechanisms that may be associated with capecitabine- induced HFS.
Förderung
- The author declared that this study has received no financial support
Zitieren
APA
Şavlı, E. (2024). Capecitabine-induced hand foot syndrome: a brief look at possible pathways that may be associated with inflammation. ODÜ Tıp Dergisi. https://doi.org/10.56941/odutip.1453500
Vancouver
Şavlı E. Capecitabine-induced hand foot syndrome: a brief look at possible pathways that may be associated with inflammation. ODÜ Tıp Dergisi. 2024. doi:10.56941/odutip.1453500
BibTeX
@article{avl2024,
author = {Şavlı, Evren},
title = {Capecitabine-induced hand foot syndrome: a brief look at possible pathways that may be associated with inflammation},
journal = {ODÜ Tıp Dergisi},
year = {2024},
doi = {10.56941/odutip.1453500}
}
EUVIMED